Vivendi FY20 Profit Down

Vivendi SA (VIV.L,VIVEF.PK) Wednesday reported full-year 2020 profit of 1.44 billion euros or 1.26 euro per share, down from 1.58 billion euros or 1.28 euro per share last year.

Adjusted net income for 2020 were 1.23 billion euros or 1.07 euro per share, down from 1.74 billion euros or 1.41 euro per share last year.

EBITA for the full year were 1.63 billion euros, up 6.6% compared to 2019.

In 2020, revenues were grew 1.2% to 16.09 billion euros from 15.90 billion euros.

Revenue growth was driven by the growth of Universal Music Group (UMG), Canal+ Group2 and Editis2, partially offset by the slowdown in other activities, mainly Havas Group and Vivendi Village, all of which were affected by the consequences of the COVID-19 pandemic.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
This Black Friday and the following holiday season, retailers across the United States are urged to keep up their inventory amid expected surge in shopping as majority of Americans wait till last minute to fill their baskets, according to certain studies. A new Oracle Retail survey, which was conducted last week and presented earlier this week, showed that 66 percent of consumers were less than Eagle, Idaho -based Flagship Food Group is recalling certain TJ Farms Select brand frozen cauliflower, citing the potential to be contaminated with Listeria monocytogenes, the U.S. Food and Drug Administration said. The recall involves a limited number of cases of TJ Farms Select cauliflower that comes in 16 oz. packages with lot code 2077890089 and UPC code 75544000604-3. The U.S. Food and Drug Administration has approved Takeda Pharmaceuticals Co. Ltd.'s Livtencity (maribavir) as the first drug to treat post-transplant cytomegalovirus or CMV in adults and pediatric patients. The approval is to treat patients 12 years of age and older and weighing at least 35 kilograms with post-transplant CMV infection/disease that does not respond...
Follow RTT